Zacks: Analysts Anticipate Crispr Therapeutics AG (CRSP) to Announce -$0.78 Earnings Per Share

Equities research analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to post ($0.78) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.89). The firm is scheduled to report its next quarterly earnings report on Thursday, March 14th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($3.26) per share for the current financial year, with EPS estimates ranging from ($3.33) to ($3.08). For the next financial year, analysts anticipate that the firm will report earnings of ($3.47) per share, with EPS estimates ranging from ($4.05) to ($1.86). Zacks’ EPS averages are an average based on a survey of research analysts that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the previous year, the company earned ($0.62) EPS. The company’s quarterly revenue was down 76.6% compared to the same quarter last year.

Several brokerages have issued reports on CRSP. Needham & Company LLC began coverage on Crispr Therapeutics in a research note on Friday, November 30th. They set a “buy” rating and a $62.00 price objective on the stock. BidaskClub cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 5th. Wells Fargo & Co began coverage on Crispr Therapeutics in a research report on Wednesday, October 10th. They set an “outperform” rating and a $65.00 price target on the stock. Zacks Investment Research upgraded Crispr Therapeutics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target on the stock in a research report on Tuesday, October 9th. Finally, Guggenheim began coverage on Crispr Therapeutics in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $59.19.

NASDAQ CRSP traded up $1.25 on Wednesday, hitting $37.13. 670,784 shares of the stock traded hands, compared to its average volume of 882,965. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90. The stock has a market capitalization of $1.86 billion, a P/E ratio of -21.71 and a beta of 3.48.

In other Crispr Therapeutics news, major shareholder Vertex Pharmaceuticals (Europe bought 22,742 shares of the stock in a transaction that occurred on Friday, December 21st. The shares were purchased at an average cost of $22.58 per share, for a total transaction of $513,514.36. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Rodger Novak sold 17,310 shares of the firm’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $35.09, for a total value of $607,407.90. Following the completion of the sale, the president now owns 1,130,697 shares in the company, valued at $39,676,157.73. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 153,682 shares of company stock worth $3,700,718. 37.70% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Crispr Therapeutics by 26.5% during the 2nd quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock valued at $553,000 after purchasing an additional 1,972 shares in the last quarter. TRUE Private Wealth Advisors bought a new position in Crispr Therapeutics during the 3rd quarter valued at $122,000. Vanguard Group Inc. boosted its stake in Crispr Therapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock valued at $2,307,000 after purchasing an additional 3,200 shares in the last quarter. Vanguard Group Inc boosted its stake in Crispr Therapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock valued at $2,307,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Crispr Therapeutics by 11.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 34,618 shares of the company’s stock valued at $1,535,000 after purchasing an additional 3,514 shares in the last quarter. Hedge funds and other institutional investors own 43.83% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Read More: What is Cost of Capital?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit